IBBQ holdings
Invesco Nasdaq Biotechnology ETF
Positions
261 stored of 261 reported, largest first by weight
| # | Holding | ISIN | CUSIP | Weight | Value (USD) | Type | Issuer type | Country | Currency |
|---|---|---|---|---|---|---|---|---|---|
| 101 | ADMA Biologics, Inc. | US0008991046 | 000899104 | 0.151% | $102K | Equity (common) | Corporate | United States | USD |
| 102 | Rapport Therapeutics, Inc. | US75383L1026 | 75383L102 | 0.151% | $102K | Equity (common) | Corporate | United States | USD |
| 103 | AbCellera Biologics Inc. | CA00288U1066 | 00288U106 | 0.149% | $100K | Equity (common) | Corporate | Canada | USD |
| 104 | Zymeworks Inc. | US98985Y1082 | 98985Y108 | 0.149% | $100K | Equity (common) | Corporate | United States | USD |
| 105 | Sarepta Therapeutics, Inc. | US8036071004 | 803607100 | 0.148% | $100K | Equity (common) | Corporate | United States | USD |
| 106 | Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals, Inc., Class A | US75629V1044 | 75629V104 | 0.148% | $100K | Equity (common) | Corporate | United States | USD |
| 107 | Nurix Therapeutics, Inc. | US67080M1036 | 67080M103 | 0.145% | $97K | Equity (common) | Corporate | United States | USD |
| 108 | Harmony Biosciences Holdings, Inc. | US4131971040 | 413197104 | 0.145% | $97K | Equity (common) | Corporate | United States | USD |
| 109 | Trevi Therapeutics, Inc. | US89532M1018 | 89532M101 | 0.143% | $97K | Equity (common) | Corporate | United States | USD |
| 110 | Novavax, Inc. | US6700024010 | 670002401 | 0.142% | $96K | Equity (common) | Corporate | United States | USD |
| 111 | Tyra Biosciences, Inc. | US90240B1061 | 90240B106 | 0.142% | $96K | Equity (common) | Corporate | United States | USD |
| 112 | uniQure N.V. | NL0010696654 | N90064101 | 0.141% | $95K | Equity (common) | Corporate | Netherlands | USD |
| 113 | Stoke Therapeutics, Inc. | US86150R1077 | 86150R107 | 0.141% | $95K | Equity (common) | Corporate | United States | USD |
| 114 | ANI Pharmaceuticals, Inc. | US00182C1036 | 00182C103 | 0.140% | $94K | Equity (common) | Corporate | United States | USD |
| 115 | Syndax Pharmaceuticals, Inc. | US87164F1057 | 87164F105 | 0.138% | $93K | Equity (common) | Corporate | United States | USD |
| 116 | Agios Pharmaceuticals, Inc. | US00847X1046 | 00847X104 | 0.136% | $92K | Equity (common) | Corporate | United States | USD |
| 117 | Genmab A/S Genmab A/S, ADR | US3723032062 | 372303206 | 0.134% | $90K | Equity (common) | Corporate | Denmark | USD |
| 118 | Iovance Biotherapeutics, Inc. | US4622601007 | 462260100 | 0.134% | $90K | Equity (common) | Corporate | United States | USD |
| 119 | Vericel Corp. | US92346J1088 | 92346J108 | 0.134% | $90K | Equity (common) | Corporate | United States | USD |
| 120 | Intellia Therapeutics, Inc. | US45826J1051 | 45826J105 | 0.131% | $88K | Equity (common) | Corporate | United States | USD |
| 121 | AtaiBeckley Inc. | US04650F1012 | 04650F101 | 0.130% | $88K | Equity (common) | Corporate | United States | USD |
| 122 | Taysha Gene Therapies Inc. | US8776191061 | 877619106 | 0.127% | $86K | Equity (common) | Corporate | United States | USD |
| 123 | Innoviva, Inc. | US45781M1018 | 45781M101 | 0.126% | $85K | Equity (common) | Corporate | United States | USD |
| 124 | Amylyx Pharmaceuticals, Inc. | US03237H1014 | 03237H101 | 0.126% | $85K | Equity (common) | Corporate | United States | USD |
| 125 | AnaptysBio, Inc. | US0327241065 | 032724106 | 0.123% | $83K | Equity (common) | Corporate | United States | USD |
| 126 | Precigen, Inc. | US74017N1054 | 74017N105 | 0.122% | $82K | Equity (common) | Corporate | United States | USD |
| 127 | Inhibrx Biosciences, Inc. | US45720N1037 | 45720N103 | 0.120% | $81K | Equity (common) | Corporate | United States | USD |
| 128 | Monte Rosa Therapeutics, Inc. | US61225M1027 | 61225M102 | 0.119% | $80K | Equity (common) | Corporate | United States | USD |
| 129 | Vir Biotechnology, Inc. | US92764N1028 | 92764N102 | 0.119% | $80K | Equity (common) | Corporate | United States | USD |
| 130 | Ardelyx, Inc. | US0396971071 | 039697107 | 0.119% | $80K | Equity (common) | Corporate | United States | USD |
| 131 | GH Research PLC | IE000GID8VI0 | G3855L106 | 0.118% | $80K | Equity (common) | Corporate | Ireland | USD |
| 132 | Fortrea Holdings Inc. | US34965K1079 | 34965K107 | 0.115% | $77K | Equity (common) | Corporate | United States | USD |
| 133 | MBX Biosciences, Inc. | US55287L1017 | 55287L101 | 0.112% | $76K | Equity (common) | Corporate | United States | USD |
| 134 | KalVista Pharmaceuticals, Inc. | US4834971032 | 483497103 | 0.109% | $74K | Equity (common) | Corporate | United States | USD |
| 135 | Bicara Therapeutics Inc. | US0554771032 | 055477103 | 0.109% | $74K | Equity (common) | Corporate | United States | USD |
| 136 | Septerna, Inc. | US81734D1046 | 81734D104 | 0.106% | $72K | Equity (common) | Corporate | United States | USD |
| 137 | UroGen Pharma Ltd. | IL0011407140 | M96088105 | 0.105% | $71K | Equity (common) | Corporate | Israel | USD |
| 138 | Harrow, Inc. | US4158581094 | 415858109 | 0.103% | $69K | Equity (common) | Corporate | United States | USD |
| 139 | Maze Therapeutics, Inc. | US5787841007 | 578784100 | 0.101% | $68K | Equity (common) | Corporate | United States | USD |
| 140 | Immunocore Holdings PLC Immunocore Holdings PLC, ADR | US45258D1054 | 45258D105 | 0.101% | $68K | Equity (common) | Corporate | United Kingdom | USD |
| 141 | ArriVent Biopharma, Inc. | US04272N1028 | 04272N102 | 0.099% | $67K | Equity (common) | Corporate | United States | USD |
| 142 | Wave Life Sciences Ltd. | SG9999014716 | Y95308105 | 0.099% | $66K | Equity (common) | Corporate | Singapore | USD |
| 143 | COMPASS Pathways PLC COMPASS Pathways PLC, ADR | US20451W1018 | 20451W101 | 0.098% | $66K | Equity (common) | Corporate | United Kingdom | USD |
| 144 | Personalis, Inc. | US71535D1063 | 71535D106 | 0.094% | $63K | Equity (common) | Corporate | United States | USD |
| 145 | MannKind Corp. | US56400P7069 | 56400P706 | 0.092% | $62K | Equity (common) | Corporate | United States | USD |
| 146 | EyePoint, Inc. | US30233G2093 | 30233G209 | 0.089% | $60K | Equity (common) | Corporate | United States | USD |
| 147 | Alvotech | LU2458332611 | L01800108 | 0.088% | $59K | Equity (common) | Corporate | Luxembourg | USD |
| 148 | Savara Inc. | US8051111016 | 805111101 | 0.084% | $57K | Equity (common) | Corporate | United States | USD |
| 149 | Collegium Pharmaceutical, Inc. | US19459J1043 | 19459J104 | 0.084% | $57K | Equity (common) | Corporate | United States | USD |
| 150 | Olema Pharmaceuticals, Inc. | US68062P1066 | 68062P106 | 0.084% | $56K | Equity (common) | Corporate | United States | USD |
| 151 | Corvus Pharmaceuticals, Inc. | US2210151005 | 221015100 | 0.082% | $55K | Equity (common) | Corporate | United States | USD |
| 152 | Xeris Biopharma Holdings, Inc. | US98422E1038 | 98422E103 | 0.081% | $55K | Equity (common) | Corporate | United States | USD |
| 153 | AbSci Corp. | US00091E1091 | 00091E109 | 0.081% | $55K | Equity (common) | Corporate | United States | USD |
| 154 | Zenas Biopharma, Inc. | US98937L1052 | 98937L105 | 0.079% | $53K | Equity (common) | Corporate | United States | USD |
| 155 | Cullinan Therapeutics, Inc. | US2300311063 | 230031106 | 0.077% | $52K | Equity (common) | Corporate | United States | USD |
| 156 | Grifols, S.A. Grifols, S.A., ADR | US3984384087 | 398438408 | 0.076% | $51K | Equity (common) | Corporate | Spain | USD |
| 157 | Pacira Biosciences, Inc. | US6951271005 | 695127100 | 0.074% | $50K | Equity (common) | Corporate | United States | USD |
| 158 | ARS Pharmaceuticals, Inc. | US82835W1080 | 82835W108 | 0.072% | $48K | Equity (common) | Corporate | United States | USD |
| 159 | Sana Biotechnology, Inc. | US7995661045 | 799566104 | 0.070% | $47K | Equity (common) | Corporate | United States | USD |
| 160 | Arbutus Biopharma Corp. | CA03879J1003 | 03879J100 | 0.070% | $47K | Equity (common) | Corporate | Canada | USD |
| 161 | Kura Oncology, Inc. | US50127T1097 | 50127T109 | 0.070% | $47K | Equity (common) | Corporate | United States | USD |
| 162 | Janux Therapeutics, Inc. | US47103J1051 | 47103J105 | 0.070% | $47K | Equity (common) | Corporate | United States | USD |
| 163 | Xencor, Inc. | US98401F1057 | 98401F105 | 0.069% | $47K | Equity (common) | Corporate | United States | USD |
| 164 | MeiraGTx Holdings PLC | KYG596651029 | G59665102 | 0.068% | $46K | Equity (common) | Corporate | Cayman Islands | USD |
| 165 | Amphastar Pharmaceuticals, Inc. | US03209R1032 | 03209R103 | 0.068% | $46K | Equity (common) | Corporate | United States | USD |
| 166 | ORIC Pharmaceuticals, Inc. | US68622P1093 | 68622P109 | 0.067% | $45K | Equity (common) | Corporate | United States | USD |
| 167 | Theravance Biopharma Inc. | KYG8807B1068 | G8807B106 | 0.065% | $44K | Equity (common) | Corporate | Cayman Islands | USD |
| 168 | Eton Pharmaceuticals, Inc. | US29772L1089 | 29772L108 | 0.064% | $43K | Equity (common) | Corporate | United States | USD |
| 169 | Geron Corp. | US3741631036 | 374163103 | 0.063% | $43K | Equity (common) | Corporate | United States | USD |
| 170 | Mesoblast Ltd. Mesoblast Ltd., ADR | US5907174016 | 590717401 | 0.063% | $43K | Equity (common) | Corporate | Australia | USD |
| 171 | Annexon, Inc. | US03589W1027 | 03589W102 | 0.063% | $42K | Equity (common) | Corporate | United States | USD |
| 172 | Omeros Corp. | US6821431029 | 682143102 | 0.062% | $42K | Equity (common) | Corporate | United States | USD |
| 173 | Phathom Pharmaceuticals, Inc. | US71722W1071 | 71722W107 | 0.060% | $41K | Equity (common) | Corporate | United States | USD |
| 174 | BioAge Labs, Inc. | US09077V1008 | 09077V100 | 0.059% | $40K | Equity (common) | Corporate | United States | USD |
| 175 | Esperion Therapeutics, Inc. | US29664W1053 | 29664W105 | 0.059% | $39K | Equity (common) | Corporate | United States | USD |
| 176 | Replimune Group, Inc. | US76029N1063 | 76029N106 | 0.056% | $38K | Equity (common) | Corporate | United States | USD |
| 177 | Maravai LifeSciences Holdings, Inc. Maravai LifeSciences Holdings, Inc., Class A | US56600D1072 | 56600D107 | 0.055% | $37K | Equity (common) | Corporate | United States | USD |
| 178 | CorMedix Inc. | US21900C3088 | 21900C308 | 0.052% | $35K | Equity (common) | Corporate | United States | USD |
| 179 | Zevra Therapeutics, Inc. | US4884452065 | 488445206 | 0.051% | $34K | Equity (common) | Corporate | United States | USD |
| 180 | Phibro Animal Health Corp. Phibro Animal Health Corp., Class A | US71742Q1067 | 71742Q106 | 0.050% | $34K | Equity (common) | Corporate | United States | USD |
| 181 | Prime Medicine, Inc. | US74168J1016 | 74168J101 | 0.050% | $34K | Equity (common) | Corporate | United States | USD |
| 182 | Vor BioPharma Inc. | US9290332074 | 929033207 | 0.050% | $34K | Equity (common) | Corporate | United States | USD |
| 183 | Castle Biosciences, Inc. | US14843C1053 | 14843C105 | 0.049% | $33K | Equity (common) | Corporate | United States | USD |
| 184 | CytomX Therapeutics, Inc. | US23284F1057 | 23284F105 | 0.048% | $32K | Equity (common) | Corporate | United States | USD |
| 185 | Candel Therapeutics, Inc. | US1374041093 | 137404109 | 0.048% | $32K | Equity (common) | Corporate | United States | USD |
| 186 | Zai Lab Ltd. Zai Lab Ltd., ADR | US98887Q1040 | 98887Q104 | 0.047% | $32K | Equity (common) | Corporate | Cayman Islands | USD |
| 187 | Design Therapeutics, Inc. | US25056L1035 | 25056L103 | 0.047% | $32K | Equity (common) | Corporate | United States | USD |
| 188 | Tectonic Therapeutic, Inc. | US8789721086 | 878972108 | 0.046% | $31K | Equity (common) | Corporate | United States | USD |
| 189 | Ironwood Pharmaceuticals, Inc. | US46333X1081 | 46333X108 | 0.046% | $31K | Equity (common) | Corporate | United States | USD |
| 190 | Arvinas, Inc. | US04335A1051 | 04335A105 | 0.045% | $30K | Equity (common) | Corporate | United States | USD |
| 191 | Solid Biosciences Inc. | US83422E2046 | 83422E204 | 0.045% | $30K | Equity (common) | Corporate | United States | USD |
| 192 | Rigel Pharmaceuticals, Inc. | US7665597024 | 766559702 | 0.044% | $29K | Equity (common) | Corporate | United States | USD |
| 193 | Aclaris Therapeutics, Inc. | US00461U1051 | 00461U105 | 0.043% | $29K | Equity (common) | Corporate | United States | USD |
| 194 | Prothena Corp. PLC | IE00B91XRN20 | G72800108 | 0.043% | $29K | Equity (common) | Corporate | Ireland | USD |
| 195 | 4D Molecular Therapeutics, Inc. | US35104E1001 | 35104E100 | 0.040% | $27K | Equity (common) | Corporate | United States | USD |
| 196 | Aquestive Therapeutics, Inc. | US03843E1047 | 03843E104 | 0.038% | $26K | Equity (common) | Corporate | United States | USD |
| 197 | Kyverna Therapeutics, Inc. | US5019761049 | 501976104 | 0.038% | $26K | Equity (common) | Corporate | United States | USD |
| 198 | Allogene Therapeutics, Inc. | US0197701065 | 019770106 | 0.038% | $26K | Equity (common) | Corporate | United States | USD |
| 199 | Aura Biosciences, Inc. | US05153U1079 | 05153U107 | 0.037% | $25K | Equity (common) | Corporate | United States | USD |
| 200 | Fulcrum Therapeutics, Inc. | US3596161097 | 359616109 | 0.036% | $24K | Equity (common) | Corporate | United States | USD |